GENEVA: Swiss drugmaker Roche said on Tuesday its experimental dual-acting obesity drug helped overweight or obese patients with type 2 diabetes lower blood sugar levels and lose an average 15.5 percent of their body weight in a mid-stage trial. Roche is racing alongside large drugmakers, including AstraZeneca and Amgen, to break into the lucrative obesity drug market and challenge leaders Eli Lilly and Novo Nordisk. Its experimental drug, enicepatide, is a once-weekly injection that mimi
